Iron-Deficiency Anemia in Ulcerative Colitis—Many Patients Don't Get Testing and Treatment

October 24, 2016 — Many patients with ulcerative colitis don't receive recommended testing and treatment for the common problem of iron deficiency anemia, reports a study in the October issue of *Inflammatory Bowel Diseases*, official journal of the Crohn’s & Colitis Foundation of America (CCFA). The journal is published by Wolters Kluwer.

About one-third of ulcerative colitis patients with anemia are not tested for iron deficiency—and nearly one-fourth of those diagnosed with iron deficiency anemia don't receive iron replacement therapy, suggests the new research by Nabeel Khan, MD, of University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues.

"Our study emphasizes the need to educate gastroenterologists and general practitioners to diagnose and treat iron deficiency anemia at an early stage," the researchers write.

'Inadequate Monitoring and Treatment' of Iron Deficiency in Patients with Ulcerative Colitis

The study used nationwide data on 836 patients newly diagnosed with ulcerative colitis in the Veterans Affairs (VA) health care system from 2001 to 2011. Over a median eight years' follow-up, 70 percent of patients developed anemia: low levels of hemoglobin, which carries oxygen in the blood.

The study focused on how many of these patients were tested and treated for iron deficiency anemia—a common complication of ulcerative colitis, caused by intestinal bleeding and malnutrition. Iron deficiency anemia has profound effects on health, including declines in physical and cognitive abilities.

The results showed "inadequate monitoring and treatment of anemia and iron deficiency" among patients with ulcerative colitis. Of the patients who developed anemia, 31 percent did not undergo recommended tests for iron deficiency. Sixty-three percent of patients tested were diagnosed with iron deficiency anemia.

However, only 76 percent of those diagnosed with iron deficiency anemia received recommended iron replacement therapy. That left about one-fourth of patients untreated, despite testing and diagnosis.

All of the treated patients received oral iron supplements. That included patients with severe anemia, for which intravenous supplementation is the preferred treatment.

Treatment rates increased with the severity of iron deficiency anemia: 55 percent in mild cases, compared to 76 percent in moderate and 91 percent in severe cases. "This finding...could explain the high prevalence of moderate to severe iron deficiency anemia in our population, as they were not treated during the early stage of their anemia," Dr. Khan and coauthors write.

The study also found some significant regional differences. Testing for iron deficiency anemia was less likely for patients in the Midwest and South regions, compared to the Northeast and West —possibly reflecting differences in physician awareness or patient follow-up care.

The researchers note some strengths and limitations of their study. While based on nationwide data, the study was limited to patients in the VA system, who may differ from the general population of ulcerative colitis patients.

Given the high prevalence and health impact of iron deficiency anemia, testing and treatment for iron deficiency should be added to the ulcerative colitis care quality indicators listed by the CCFA and the American...
Gastroenterology Association, Dr. Khan and colleagues believe. They write, "Testing and treatment are both easily measurable parameters, and emphasizing their importance will lead to better patient outcomes."

Note to editors: For further information, contact Jeanine Kober, Communications Manager for CCFA: phone 646-943-7481 or e-mail jkober@ccfa.org.

Click here to read "Factors Predicting Testing and Treatment of Iron Deficiency in a Nationwide Cohort of Anemic UC Patients."

Article: "Factors Predicting Testing and Treatment of Iron Deficiency in a Nationwide Cohort of Anemic UC Patients" (doi: 10.1097/MIB.0000000000000947)

###

About Inflammatory Bowel Diseases

*Inflammatory Bowel Diseases* brings the most current information in clinical and basic sciences to physicians caring for patients with inflammatory bowel diseases, and investigators performing research in IBD and related fields. Each issue contains cutting-edge original basic science and clinical articles on diagnosis, treatment, and management of IBD from clinicians and researchers around the world. Coverage includes articles highlighting the unique and important issues in pediatric IBD, as well as articles pertaining to adult patients.

About CCFA

The [Crohn's & Colitis Foundation of America](https://ccfa.org) (CCFA) is the largest voluntary non-profit health organization dedicated to finding cures for Inflammatory Bowel Diseases (IBD). CCFA's mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research, providing educational resources for patients and their families, medical professionals, and the public, and furnishing supportive services for those afflicted with IBD. For more information, visit [www.ccfa.org](http://www.ccfa.org), call 888-694-8872, like us on Facebook, or follow us on Twitter.

About Wolters Kluwer

Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit [www.wolterskluwer.com](http://www.wolterskluwer.com), follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.

Media Contact:

Connie Hughes  Ellen Robinson
Director, Corporate Communications  Public Relations Assistant
Health Learning, Research & Practice  Health Learning, Research & Practice
+1 (646) 674-6348  +1 (646) 674-6636
[Connie.Hughes@wolterskluwer.com](mailto:Connie.Hughes@wolterskluwer.com)  [Ellen.Robinson@wolterskluwer.com](mailto:Ellen.Robinson@wolterskluwer.com)